Despite being the most common cancer diagnosed in men in the U.S., and a growing burden worldwide, an understanding of the molecular mechanisms underlying susceptibility for prostate cancer (PCa) remains elusive, particularly with respect to inherited risk for clinically relevant, aggressive PCa. Segregation analyses and twin studies are consistent with an important genetic component for PCa risk, providing a strong basis for linkage analyses of PCa families undertaken by research groups in the U.S. and Europe and resulting in implication of many different loci as potentially harboring PCa susceptibility genes. These initial studies emphasize the extensive heterogeneity that characterizes familial PCa. To address and overcome the difficulties that this heterogeneity presents for PCa susceptibility gene mapping and identification, the International Consortium for Prostate Cancer Genetics (ICPCG) was established. This consortium consists of researchers from over 20 institutions in 7 different countries in North America, Europe and Australia, all of whom have extensive, ongoing research programs in this area. Together, this group has collected DNA samples from over 2600 prostate cancer families, including families with 3 or more members affected with aggressive prostate cancer. The size and diversity of this consortium make it ideally suited to address questions in molecular genetics of prostate cancer, including those involving susceptibility gene identification, genetic heterogeneity, other cancers segregating in prostate cancer families, and gene frequency and penetrance of PCa genes once they are identified. In this proposal, we seek the further development and use of the combined resources of the ICPCG to perform systematic analyses to identify and characterize prostate cancer susceptibility genes. Specifically, we propose to: 1) Define the most likely regions harboring prostate cancer susceptibility genes by combining genome wide scan linkage results from -2000 prostate cancer families (including over 110 African American PCa families), with special emphasis on subsets of families with early age at diagnosis, large numbers of affected individuals, and multiple cases with features of clinically aggressive disease;2) Perform fine mapping in these regions to narrow the region of interest (ROI);3) Perform dense SNP genotyping to identify and evaluate candidate genes associated with PCa risk in narrowed ROI;4) Confirm and further characterize any SNPs associated with PCa risk in independent case-control populations;5) Search for rare variants accounting for linkage in regions where no association is observed. It is anticipated that this combined resource and the studies made possible by its continued analysis will provide an unprecedented opportunity to characterize and unravel the complexities of genetic susceptibility for this common disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-5 (M1))
Program Officer
Seminara, Daniela
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Cooney, Kathleen A (2017) Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact. Trans Am Clin Climatol Assoc 128:14-23
Woo, Daniel; Debette, Stephanie; Anderson, Christopher (2017) 20th Workshop of the International Stroke Genetics Consortium, November 3-4, 2016, Milan, Italy: 2016.036 ISGC research priorities. Neurol Genet 3:S12-S18
Winter, Jean M; Gildea, Derek E; Andreas, Jonathan P et al. (2017) Mapping Complex Traits in a Diversity Outbred F1 Mouse Population Identifies Germline Modifiers of Metastasis in Human Prostate Cancer. Cell Syst 4:31-45.e6
Larson, Nicholas B; McDonnell, Shannon K; Fogarty, Zach et al. (2017) Network-directed cis-mediator analysis of normal prostate tissue expression profiles reveals downstream regulatory associations of prostate cancer susceptibility loci. Oncotarget 8:85896-85908
Karyadi, Danielle M; Geybels, Milan S; Karlins, Eric et al. (2017) Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies TANGO2, OR5H14, and CHAD as new prostate cancer susceptibility genes. Oncotarget 8:1495-1507
Leapman, Michael S; Cowan, Janet E; Nguyen, Hao G et al. (2017) Active Surveillance in Younger Men With Prostate Cancer. J Clin Oncol 35:1898-1904
Larson, Nicholas B; McDonnell, Shannon; Cannon Albright, Lisa et al. (2017) gsSKAT: Rapid gene set analysis and multiple testing correction for rare-variant association studies using weighted linear kernels. Genet Epidemiol 41:297-308
Luedeke, Manuel; Rinckleb, Antje E; FitzGerald, Liesel M et al. (2016) Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status. Hum Mol Genet 25:5490-5499
Ioannidis, Nilah M; Rothstein, Joseph H; Pejaver, Vikas et al. (2016) REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum Genet 99:877-885
Teerlink, Craig C; Leongamornlert, Daniel; Dadaev, Tokhir et al. (2016) Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. Hum Genet 135:923-38

Showing the most recent 10 out of 70 publications